Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | HTR7 | P34969 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567360 | 1.00 | HTR1A (0.40) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL26807639 | 0.89 | TSHR (0.47) | HTR1AHTR7TSHRSMN1; SMN2KEAP1 | |
| SCHEMBL26807637 | 0.85 | HTR1A (0.40) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL24309983 | 0.85 | HTR1A (0.39) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL26810543 | 0.84 | HTR1A (0.39) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL29566960 | 0.84 | HTR1A (0.39) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL24309834 | 0.84 | HTR1A (0.39) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL24309574 | 0.82 | BRD4 (0.41) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL29567022 | 0.82 | BRD4 (0.41) | HTR1AHTR7TSHRSMN1; SMN2DRD2 | |
| SCHEMBL29566619 | 0.82 | HTR1A (0.43) | HTR1AHTR7TSHRSMN1; SMN2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR1A 4018/4885HTR7 3833/4885TSHR 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.